The role of SGLT-2 inhibitors (Empagliflozin) in the management of glucocorticoid induced hyperglycaemia in adults with and without diabetes

Endocrinology Department, Gosford Hospital0 个研究点目标入组 30 人开始时间: 2020年7月20日最近更新: 2020年7月27日

试验速览

暂无简介。

•Inclusion criteria
•Informed consent
•Adults aged 18 years old and older
•Patients on Glucocorticoid therapy equivalent to 10mg prednisolone or more with planned duration of treatment for at
•least 4 weeks
•Patients without prior history of diabetes
•Patients with pre-existing diabetes on single agent metformin therapy
•2 blood glucose readings measuring more than 10mmol/L within a 24 hour period OR
•1 random blood glucose reading measuring more than 15mmol/L

•Renal impairment eGFR less than 45ml/minute
•Poor oral intake or patient on a low carbohydrate or ketogenic diet
•Patient states that they are actively following a low carbohydrate diet which is
•less than 130grams of carbohydrates a day
•Patient states that they are actively following a ketogenic diet which is 20-50grams of carbohydrates a day
•Patient with active malignancy
•History of recurrent genitourinary infections
•Need for ICU admission at the time of recruitment
•Current use of SGLT-2 inhibitors
•Acute CVA in the past 2/12
•Pregnancy/ Breast feeding
•Volume depletion at the time of recruitment (gastroenteritis, acute kidney injury, fluid restriction of 1.5litres/day)
•Inability to consent

发起方

Endocrinology Department, Gosford Hospital